awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q41386664-316F9152-1D81-423F-B7B2-9269C6CB151F
Q41386664-316F9152-1D81-423F-B7B2-9269C6CB151F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41386664-316F9152-1D81-423F-B7B2-9269C6CB151F
Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.
P2860
Q41386664-316F9152-1D81-423F-B7B2-9269C6CB151F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41386664-316F9152-1D81-423F-B7B2-9269C6CB151F
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
220e39875189e3bb9da07df3ee58a64cbbcefb4a
P2860
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis